about
Therapeutic Lymphoid Organogenesis in the Tumor MicroenvironmentDifferential transcriptome profile of peripheral white cells to identify biomarkers involved in oxaliplatin induced neuropathy.Transcriptional landscape of psoriasis identifies the involvement of IL36 and IL36RN.Limited Contribution of IL-36 versus IL-1 and TNF Pathways in Host Response to Mycobacterial Infection.Interleukin (IL)-1β Is a Strong Inducer of IL-36γ Expression in Human Colonic Myofibroblasts.IL-36γ Transforms the Tumor Microenvironment and Promotes Type 1 Lymphocyte-Mediated Antitumor Immune Responses.Elucidating drivers of oral epithelial dysplasia formation and malignant transformation to cancer using RNAseq.Distinct expression of interleukin (IL)-36α, β and γ, their antagonist IL-36Ra and IL-38 in psoriasis, rheumatoid arthritis and Crohn's disease.Tbet and IL-36γ cooperate in therapeutic DC-mediated promotion of ectopic lymphoid organogenesis in the tumor microenvironment.IL-36γ is a crucial proximal component of protective type-1-mediated lung mucosal immunity in Gram-positive and -negative bacterial pneumonia.IRF6 Regulates the Expression of IL-36γ by Human Oral Epithelial Cells in Response to Porphyromonas gingivalis.Application of IL-36 receptor antagonist weakens CCL20 expression and impairs recovery in the late phase of murine acetaminophen-induced liver injury.IL-36γ is secreted in microparticles and exosomes by lung macrophages in response to bacteria and bacterial componentsInterleukin-36γ is expressed by neutrophils and can activate microglia, but has no role in experimental autoimmune encephalomyelitis.Regulation and function of interleukin-36 cytokines.The inflammasome potentiates influenza/Staphylococcus aureus superinfection in mice.
P2860
Q26799123-FF0C0D1D-12E2-480C-9221-A3AD0006F72EQ34683946-0C7EBD5C-0AC8-47C0-894F-6DD03D0C5C8FQ35519210-A0A10BF8-E421-496D-A18B-6E49B633AFD0Q35623978-94136C82-7E74-4388-812C-516EC6FA2AF9Q35839978-24A77DD7-AFFA-402A-A3A3-36B9746CF6DBQ36070562-41CE53A4-D760-4988-9F64-798F72F85B62Q38261799-5B983D01-91C3-4052-AC7F-8DE0A9063204Q38809309-D0C7AB08-FAD4-4D63-AAE1-51FC8FB10030Q40146273-27E35684-F477-4EFE-B625-19843CE00020Q40340613-BB563202-F8C3-409A-9C44-218FB8E04F2FQ40815050-8A8C950B-C412-48CF-B369-B4BD048C283CQ41480019-5CC55C49-401E-4118-9553-09E444914417Q41768407-BA44228B-68F8-4545-99C8-A2A10E39845FQ41825896-4FC26323-5B57-4726-B83A-5A16CEC24602Q47298022-ECB0DC12-1CF1-4C62-A562-EDC19E4C392AQ52606460-E1577331-164A-476F-924D-3C0B569340E3
P2860
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
IL-36γ/IL-1F9, an innate T-bet target in myeloid cells.
@en
IL-36γ/IL-1F9, an innate T-bet target in myeloid cells.
@nl
type
label
IL-36γ/IL-1F9, an innate T-bet target in myeloid cells.
@en
IL-36γ/IL-1F9, an innate T-bet target in myeloid cells.
@nl
prefLabel
IL-36γ/IL-1F9, an innate T-bet target in myeloid cells.
@en
IL-36γ/IL-1F9, an innate T-bet target in myeloid cells.
@nl
P2093
P2860
P356
P1476
IL-36γ/IL-1F9, an innate T-bet target in myeloid cells
@en
P2093
Josef Pfeilschifter
Lorena Härdle
Malte Bachmann
Patrick Scheiermann
P2860
P304
41684-41696
P356
10.1074/JBC.M112.385443
P407
P50
P577
2012-10-24T00:00:00Z